Ocean Biomedical(OCEA)
$0.00-0.00 (-33.33%)
OCEA
Ocean Biomedical financials statements
$0.00
At close:-0.00 (-33.33%)
Ocean Biomedical (OCEA) Ratios
283 Followers
Ocean Biomedical Ratios
OCEA's free cash flow for Q1 2025 was $-356.00K. For the 2025 fiscal year, OCEA's free cash flow was increased by $0.00 and operating cash flow was $-356.00K. See a summary of the company’s cash flow.
| Ratios | Dec 24 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.02 | 0.14 | 6.29 | 0.17 | 0.00 |
| Quick Ratio | 0.02 | 0.14 | 6.29 | 0.17 | 0.00 |
| Cash Ratio | 0.01 | 0.09 | 4.36 | 0.00 | 0.00 |
| Solvency Ratio | -0.03 | 0.09 | -18.29 | -0.64 | -0.26 |
| Operating Cash Flow Ratio | -0.12 | -0.22 | -4.27 | -0.03 | 0.00 |
| Short-Term Operating Cash Flow Coverage | -0.26 | -0.35 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -97.71M | $ -6.15M | $ -1.85M | $ -1.89M | $ -232.00K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 18.07 | 0.02 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | -0.17 | 0.02 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | -0.20 | 0.02 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.01 | 1.06 | 1.03 | -0.20 | 0.00 |
| Debt Service Coverage Ratio | -0.52 | -0.45 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 1.86 | -3591.37 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.52 | 0.11 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | -2.16 | -1.90 | 3.28 | 0.00 | 0.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | -59.00% | 11051.75% | 100.00% | 100.00% |
| EBT Per EBIT | 86.91% | 38.62% | 99.57% | 100.06% | 100.00% |
| Return on Assets (ROA) | -365.96% | 0.51% | -57.38% | -428.24% | 0.00% |
| Return on Equity (ROE) | 3.38% | 0.54% | -59.23% | 87.69% | 100.00% |
| Return on Capital Employed (ROCE) | 11.51% | -2.31% | -0.52% | 87.64% | 100.00% |
| Return on Invested Capital (ROIC) | 22.76% | -2.26% | -0.52% | 87.64% | 100.00% |
| Return on Tangible Assets | -365.96% | 0.51% | -57.38% | -428.24% | 0.00% |
| Earnings Yield | -21.70% | 0.29% | -47.19% | -0.82% | -0.12% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.15 | -0.04 | -0.08 | -0.00 | 0.00 |
| Free Cash Flow Per Share | -0.15 | -0.04 | -0.08 | -0.00 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -249099.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -249099.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.26 | -0.35 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -27.48% | -0.38% | -0.80% | -0.03% | 0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.61 | 349.88 | -2.12 | -121.86 | -868.23 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.16 | 1.90 | 1.26 | -106.86 | -868.23 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.64 | -264.75 | -125.47 | -3147.32 | 0.00 |
| Price-to-Operating Cash Flow Ratio | -3.64 | -264.75 | -125.47 | -3147.32 | 0.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 31.05 | 0.04 | -0.20 | 0.00 |
| Enterprise Value Multiple | -7.39 | -529.24 | -1026.38 | -311.26 | -2216.39 |
| Enterprise Value | 54.90M | 506.88M | 336.19M | 514.20M | 514.20M |
| EV to EBITDA | -7.39 | -529.24 | -1026.38 | -311.26 | -2216.39 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -13.13 | -678.28 | -319.27 | -8034.41 | 0.00 |
| EV to Operating Cash Flow | -13.13 | -678.28 | -319.27 | -8034.41 | 0.00 |
| Tangible Book Value Per Share | -3.55 | 5.48 | 7.96 | -0.09 | -0.01 |
| Shareholders’ Equity Per Share | -3.55 | 5.48 | 7.96 | -0.09 | -0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.12 | 0.03 | -4.71 | -0.08 | -0.01 |
| Tax Burden | 1.00 | -0.59 | 110.52 | 1.00 | 1.00 |
| Interest Burden | 0.44 | 1.00 | 1.00 | 0.00 | 0.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.44 | 0.78 | 0.02 | 0.04 | 0.00 |
Currency in USD
